A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
Project objectives
A randomized, double-blind, placebo-controlled, multicenter phase III study of apalutamide in combination with a GnRH agonist in patients with high-risk localized or locally advanced prostate cancer undergoing radiotherapy. This study aims to evaluate whether apalutamide in combination with a GnRH agonist improves metastasis-free survival.
Start and end date
21/09/2019 - ongoing
Project managers
Prof. Lucio Trodella
Coordinating institution of the project
Radiation Oncology, European Institute of Oncology
Funding sources
Janssen-Cilag SPA
